Generic Producer To Cut Production
After FDA officials and investigators identified a series of quality issues at a manufacturing facility in Telengana, India, Aurobindo halted the production of a number of products.
This compounds existing concerns about the availability and quality of some generic medications, and partial shutdowns at a major production plant could exacerbate those worries. The facility is run by Eugia Pharma Specialties, a subsidiary of Aurobindo. They produce about 150 different items, including injectables and eye drops for the US market. It also manufactures roughly 30 products that are sold by Walgreens and other businesses.
Among the drugs produced in the Telengana factory that are scarce in the US are injections of dexamethasone sodium phosphate and methylprednisolone acetate.
The facility’s quality-control problems are a reflection of the FDA's continuous struggles. The agency's inspection activity has drastically declined despite the unsatisfactory performance of numerous foreign pharmaceutical facilities. Violations concerning product testing, paperwork, and contamination have been brought to the attention of several Indian corporations. US lawmakers have taken notice of their disregard for sound manufacturing techniques and the impact this has had on the supply chain.